1

2

Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy

3

4 5 7 8 9 10 11 12 13 14	Michal Juraska ^{*a,1} , Ph.D., Angela M. Early ^{a,2} , Ph.D., Li Li ¹ , Ph.D., Stephen F. Schaffner ² , Ph.D., Marc Lievens ³ , M.Sc., Akanksha Khorgade ² , M.Sc., Brian Simpkins ¹ , B.A., Nima S. Hejazi ⁴ , Ph.D., David A. Benkeser ⁵ , Ph.D., Qi Wang, B.Eng. ⁶ , Laina D. Mercer ⁷ , Ph.D., Samuel Adjei ⁸ , M.B., Ch.B., D.T.M., Tsiri Agbenyega ⁸ , M.B., Ch.B., Ph.D., Scott Anderson ² , B.S., Daniel Ansong ⁸ , M.B., Ch.B., F.W.A.C.P., Dennis K. Bii ⁹ , M.B.Ch.B, M.P.H., Patrick B.Y. Buabeng ⁸ , M.B.A., Sean English ² , B.S., Nicholas Fitzgerald ² , B.S., Jonna Grimsby ² , Ph.D, Simon K. Kariuki ⁹ , Ph.D., Kephas Otieno ⁹ , M.Sc., François Roman ³ , M.D., Aaron M. Samuels ^{10,11} , M.D., Nelli Westercamp ¹¹ , Ph.D., Christian F. Ockenhouse ⁷ , M.D., Ph.D., Opokua Ofori-Anyinam ³ , Ph.D., Cynthia K. Lee ⁷ , Ph.D., Bronwyn L. MacInnis ² , Ph.D., Dyann F. Wirth ^{2,12} , Ph.D., Peter B. Gilbert ^{1,13} , Ph.D., Daniel E. Neafsey ^{*2,12} , Ph.D.
15	^a These authors contributed equally to this manuscript
16 17	1. Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, WA, USA
18 19	2. Broad Institute, Infectious Disease and Microbiome Program, Cambridge, MA, USA
20 21	3. GSK, Wavre, Belgium
22 23	4. Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, MA, USA
24 25 26	5. Rollins School of Public Health, Department of Biostatistics and Bioinformatics, Atlanta, GA, USA
27 28	6. Department of Statistics, University of Washington, Seattle, WA, USA
29 30	7. PATH, Seattle, WA, USA
31 32 33	8. Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana
34 35	9. Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
36 37 38	10. Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Kisumu, Kenya
39 40	11. Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA

- 41
- 42 12. Harvard T.H. Chan School of Public Health, Department of Immunology and Infectious
- 43 Diseases, Boston, MA, USA
- 44
- 45 13. Department of Biostatistics, University of Washington, Hans Rosling Center for Population
- 46 Health, Seattle, WA, USA
- 47
- 48 * To whom reprint requests should be addressed

49 **Corresponding authors:**

- 50 Michal Juraska (mjuraska@fredhutch.org); Daniel E. Neafsey (neafsey@broadinstitute.org)
- 51
- 52

53 Abstract

54 Background

- 55 The only licensed malaria vaccine, RTS,S/AS01_E, confers moderate protection against
- 56 symptomatic disease. Because many malaria infections are asymptomatic, we conducted a
- 57 large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how
- 58 vaccine dosing regimen affects vaccine efficacy (VE).

59 Methods

- 60 1,500 children aged 5–17 months were randomized to receive four different RTS,S/AS01_E
- 61 regimens or a rabies control vaccine in a phase 2b clinical trial in Ghana and Kenya. We
- 62 evaluated the time to the first new genotypically detected infection and the total number of new
- 63 infections during two follow-up periods in over 36K participant specimens. We performed a post
- 64 hoc analysis of VE based on malaria infection status at first vaccination and force of infection.

65 Results

- 66 We observed significant and comparable VE (25–43%, 95% CI union 9–53%) against first new
- 67 infection for all four RTS,S/AS01_E regimens across both follow-up periods (12 and 20 months).
- 68 Each RTS,S/AS01_E regimen significantly reduced the number of new infections in the 20-month
- 69 follow-up period (control mean 4.1 vs. RTS,S/AS01_E mean 2.6–3.0). VE against first new
- infection was significantly higher in participants who were malaria-infected (68%; 95% CI, 50 to
- 80%) versus uninfected (37%; 95% CI, 23 to 48%) at the first vaccination (P=0.0053) and in
- 72 participants experiencing greater force of infection between dose 1 and 3 (P=0.059).

73 Conclusions

- All tested dosing regimens blocked some infections to a similar degree. Improved VE in
- 75 participants infected during vaccination could suggest new strategies for highly efficacious
- 76 malaria vaccine development and implementation. (ClinicalTrials.gov number, NCT03276962)
- 77

78 Introduction

Malaria infection by the *Plasmodium falciparum* parasite causes over 230 million cases and
600,000 deaths per year, and progress in reducing morbidity and mortality through vector
control and drug treatment has stalled.¹ RTS,S/AS01_E (hereafter referred to as RTS,S; GSK,
Wavre, Belgium) is the first vaccine recommended for *P. falciparum* malaria by the World Health
Organization and it provides moderate protective efficacy against clinical malaria. Improving
protective efficacy is a major goal of ongoing work, including testing alternative dosing
schedules and gaining a greater understanding of the mechanism of protection.

86 Most malaria vaccine trials evaluate vaccine efficacy (VE) using clinical disease as an 87 endpoint, but enhanced understanding of the mechanism and magnitude of protection may be 88 gained from molecular detection of new infections, given that a large proportion of malaria infections are asymptomatic.² Here we report on the MAL-095 study, a genotyping investigation 89 90 of infection endpoints employing samples from the MAL-094 phase 2b randomized controlled 91 trial of RTS,S. The MAL-094 trial enrolled 5-17 month-old children in Ghana and Kenya and 92 used clinical disease endpoints to investigate the effect of dosing regimen on VE, ultimately 93 finding no significant differences in VE against clinical disease between a delayed third dose 94 regimen (R017), a fractional third dose regimen (Fx012), and the standard full dose regimen (R012).³ 95

To explore protection in that study using a molecular infection endpoint, we genotyped > 96 97 36,000 blood samples taken both at symptomatic clinic visits and at monthly cross-sectional 98 timepoints. We used a genotyping assay that detects infections at a sub-microscopic level and 99 distinguishes newly incident superinfections from persistent asymptomatic infections, yielding 100 the capacity to measure both the time to first new infection and the cumulative number of new 101 parasite infections post-vaccination. We additionally assessed VE according to genotype of the 102 infecting parasites given the previous observation of allele-specific VE in the phase 3 RTS,S 103 trial.⁴ Because our genotyping assay detects newly incident superinfections in individuals with 104 pre-existing infections, we performed a post hoc analysis of VE based on infection status at first

- 105 vaccination to test the common hypothesis cited in other recent studies that an erythrocytic
- 106 malaria infection during vaccination impairs development of a protective immune response.^{5,6}

107 Methods

- 108 Study Design and Sequence-Data Generation
- 109 As described fully in the primary analysis of the parent study evaluating protection against
- 110 clinical disease,³ participants 5–17 months in age were enrolled at study sites in Agogo, Ghana,
- and Siaya, Kenya (750 per site), and randomly assigned into one of five vaccination groups
- 112 (1:1:1:1). The control rabies vaccination group was vaccinated at months 0, 1, and 2.
- 113 Participants in the RTS,S groups received two full doses at months 0 and 1 and either full doses
- at months 2 and 20 (group R012-20), full doses at months 2, 14, 26, and 38 (group R012-14),
- fractional doses at months 2, 14, 26, and 38 (group Fx012-14; early fourth dose), or fractional
- doses at months 7, 20, and 32 (group Fx017-20; delayed third dose; Fig. S1–S3 in the
- 117 Supplementary Appendix).

118 Participant samples were collected as dried blood spots (DBS) on Whatman FTA sample 119 cards at the baseline enrollment visit (M0), cross-sectionally at monthly intervals until study 120 month 20, and during febrile clinic visits. Blood smears were collected for microscopy-based 121 detection of infection. For asymptomatic individuals, blood smears were evaluated at a later 122 date and did not trigger treatment to clear infection. Participants meeting the primary or 123 secondary case definitions of malaria were treated according to the national guidelines of each 124 country, with the primary case definition being >5000 asexual parasites per uL and fever 125 (axillary temperature \geq 37.5°C), and the secondary case definition being any parasitemia > 0

and fever or history of fever within 24 h of presentation.

127 We analyzed all DBS samples by extracting DNA and performing Illumina-based 128 amplicon sequencing of the cs C-terminus coding region (cs) and a comparably polymorphic 129 coding region for the antigen sera2. We defined distinct haplotypes as the combined genotype 130 of all nucleotide variants in a given amplicon sequence. Complexity of Infection (COI) was 131 defined as the maximum number of distinct haplotypes detected in a sample at either amplicon. 132 We declared a new parasite infection on a specific sampling date if at least one haplotype was 133 observed for either amplicon that had not been previously detected in the preceding three 134 samples from that individual. Haplotype diversity was high at both study sites for both the cs and 135 sera2 amplicons (Fig. S4 in the Supplementary Appendix). A full description of molecular 136 methods, data filtration, and sequence analysis is in the Supplementary Appendix. All MiSeq 137 data were submitted to the NCBI Sequence Read Archive (BioProject PRJNA983279). 138 139 Study Oversight 140 The trial (MAL-095; NCT03281291) and its parent study (MAL-094; NCT03276962) were 141 sponsored by GlaxoSmithKline Biologicals SA, the vaccine developer and manufacturer, and 142 funded by both GlaxoSmithKline Biologicals SA and the PATH Malaria Vaccine Initiative, which 143 received a grant from the Bill and Melinda Gates Foundation. The trial protocol was approved by 144 all relevant ethical review boards and signed or witnessed thumbprint informed consent was

146

145

147 <u>Statistical Analysis</u>

All analyses planned prior to the execution of this study are described in the Statistical Analysis
Plan (SAP) included in the Supplementary Appendix. In short, we first assessed VE of each
RTS,S regimen vs. rabies control and relative VE comparing RTS,S regimens head-to-head to
prevent the first new genotypic infection and to reduce the number of new genotypic infections.
These analyses were performed in parallel for the Exposed Set (ES) of participants who

obtained from the children's parents or guardians prior to participation.

received the first vaccine dose (**Fig. S2** in the Supplementary Appendix) and the Per-Protocol Set (PP) of participants who received the first 3 doses per protocol and were in follow-up at 14 days after the third dose (**Fig. S3** in the Supplementary Appendix). We analyzed the follow-up period from the first dose to the month 20 visit in the ES and from 14 days after the third dose to a visit scheduled 12 months after the third dose in the PP.

158 To study vaccine effects on time to the first new infection, we defined VE as one minus 159 the hazard ratio (RTS,S vs. control) of the first new infection estimated using the Cox 160 proportional hazards model with 95% Wald confidence intervals (CIs) and two-sided Wald tests 161 of zero VE. For RTS,S head-to-head comparisons, relative VE was defined analogously 162 replacing the control with an active comparator regimen. Further, we estimated instantaneous VE over time with 95% pointwise and simultaneous CIs using nonparametric kernel-smoothing⁷ 163 164 and tested for variation in VE across time⁸. Cumulative incidence of the first new infection was 165 estimated using the transformed Nelson-Aalen estimator for the cumulative hazard function. 166 We measured vaccine effects on the number of new infections by the additive difference 167 (RTS,S vs. comparator) in the mean number of new infections. The infection count was defined 168 as unobserved if the number of missed visits or samples exceeded a specified threshold (Supplementary Appendix). We assessed the mean difference by targeted maximum likelihood 169 estimation (TMLE)⁹ accounting for unobserved infection counts. Additionally, we employed 170 171 TMLE to estimate reverse cumulative distribution functions of the number of new infections in 172 each study group.

Besides overall VE, we assessed in the PP whether and how VE against the first new
infection depended on genotypic characteristics of infecting parasites using augmented inverse
probability weighting^{10,11} and their complete-case analogs¹² (details in Supplementary
Appendix).

177 Finally, we assessed whether baseline parasite positivity and/or infection risk modified
178 the effect of RTS,S on the time to the first new genotypic infection and the time to the first new

179 clinical malaria episode. Covariate-adjusted Cox proportional hazards models with separate 180 baseline hazards for each study site, employing 95% Wald Cls and Wald interaction tests, and 181 Nelson-Aalen-based cumulative incidence curves were used. We performed a sensitivity 182 'matching' Cox analysis with stratified sampling, wherein baseline negative participants were 183 randomly sampled from the same randomization group and study site by matching baseline 184 positive participants on the date of the third vaccination to address potential confounding by low-185 vs. high-transmission season. Additionally, a sensitivity analysis with E-values quantified the 186 robustness of evidence for baseline parasite positivity and M2-FOI causally modifying vaccine 187 efficacy (details in Supplementary Appendix).

188 All aforementioned analyses were performed on pooled data from both study sites as 189 well as separately within each site. Tests for VE departing from 0 were adjusted for multiplicity 190 separately within each analysis cohort, study site-pooled vs. -specific analysis, and each of the 191 three sets of treatment comparison types defined as follows: comparisons vs. the control 192 regimen other than the primary comparisons of each of Fx012-14 and Fx017-20 vs. control, 193 comparisons vs. the "standard" RTS,S regimen R012-20, and head-to-head comparisons of 194 novel RTS,S regimens (details in the Supplementary Appendix). For each multiplicity set, P-195 value adjustments were implemented to control the familywise error rate (FWER) (Holm-Bonferroni¹³) and the false discovery rate (FDR) (Q-values; Benjamini-Hochberg¹⁴). We defined 196 197 FWER statistical significance as an FWER-adjusted P-value ≤ 0.05 and FDR statistical 198 significance as a Q-value ≤ 0.2 together with an unadjusted P-value ≤ 0.05 . All P-values are two-sided except P-values testing differential VE by 3D7 Hamming distances and by COI, which 199 200 are double one-sided. 201

202 **Results**

203 Participants and Genotypic Endpoints

The ES comprised 1,500 children (750 per study site), with 36,080 specimens collected 204 205 between the first dose and the month 20 visit and 35,456 (98.3%) with genotyping completed 206 (Fig. S2 in the Supplementary Appendix). Of those, 5,078 (14.3%) were confirmed parasite-207 positive, among which 3.937 (77.5%) were associated with a new infection. The PP comprised 208 1,332 children (687 in Agogo and 645 in Siava), with 34,147 specimens collected during the PP 209 follow-up period (14 days to 12 months after the third dose) and 33,547 (98.2%) with genotyping 210 completed (Fig. S3 in the Supplementary Appendix). Of those, 4,746 (14.1%) were confirmed 211 parasite-positive, among which 3,690 (77.7%) were associated with a new infection. In the ES 212 and PP, 1,030 (68.7%) and 763 (57.3%) participants, respectively, experienced the first new 213 genotypic infection during the respective follow-up. The median time from the first (third) dose to 214 the first new infection in the ES (PP) was 40.9 (37.0) weeks. The mean number of new 215 genotypic infections per individual was 2.9 and 1.5 in the ES and PP, respectively. 216

217 Vaccine Efficacy against First New Infection

218 VE of each RTS,S regimen vs. the control regimen was 25–31% (95% CI union, 9 to 43) in the

ES and 37–43% (95% CI union, 21 to 53) in the PP, each significantly different from zero (all

P<0.0033 in the ES and <0.001 in the PP) (Fig. 1 and Fig. S5 in the Supplementary Appendix).

221 No significant differences in the hazard rate of the first new infection were found in head-to-head

comparisons of RTS,S regimens (all P>0.32) (Fig. S6 in the Supplementary Appendix).

223 Instantaneous VE over time suggests that the full dose at month 2 may have provided a more

sustained protection than a fractional dose at month 2, as VE of Fx012-14 waned to zero by 7

225 months after the third dose (**Fig. S7** in the Supplementary Appendix).

226

227 Vaccine Efficacy to Reduce Number of New Infections

228	The mean number of new infections in RTS,S recipients was significantly lower than that in
229	control recipients in both the ES and PP (all P<0.001) (Fig. 2 and Fig. S8 in the Supplementary
230	Appendix). In the ES, the mean new infection count during 20 months ranged between 2.6–3.0
231	among RTS,S recipients and was 4.1 among control recipients, with the mean difference
232	ranging -1.6 to -1.1 (95% CI union, -2.1 to -0.6). In the PP, the mean new infection count
233	between 14 days and 12 months after the third dose ranged between 1.4–1.5 among RTS,S
234	recipients and was 2.2 and 2.7 among control recipients between months 2.5–14 or 7.5–19,
235	respectively, with the mean difference ranging -1.3 to -0.8 (95% CI union, -1.6 to -0.4).
236	
237	Haplotype Variation
238	RTS,S regimens diminished the COI of the first new infection compared to the control regimen
239	in the PP (Fig. 3A and 3C). Moreover, RTS,S regimens exhibited a significantly greater
240	reduction in the risk of more highly polyclonal first new infections (Fig. 3B and 3D). The
241	estimated risk reduction of pooled R012-14, R012-20, and Fx012-14 vs. control was 29% (95%
242	CI, 13 to 42) against single-haplotype first new infections and 76% (95% CI, 58 to 86) against
243	first new infections with 5 haplotypes (P<0.001 for increasing risk reduction with COI).
244	The genotypic sieve analysis was underpowered given the low 3D7 prevalence and
245	small endpoint counts. No evidence was found for differential VE against the first new infection
246	with a perfect amino acid residue match vs. mismatch to the 3D7 vaccine strain in the cs C-
247	terminus full amplicon or haplotypic regions (Fig. S9 in the Supplementary Appendix). There
248	was a non-significant trend of a VE decline with an increasing degree of residue mismatch to
249	3D7 in the cs C-terminus (Figure S10 in the Supplementary Appendix). Scanning individual
250	polymorphic amino acid positions, we found hypothesis-generating signals of differential VE of
251	Fx012-14 against first new infection strains with a match vs. mismatch to a 3D7 residue at cs C-
252	terminus codon positions 322, 324, and 327 in Th2R (Fig. S11-S14 in the Supplementary
253	Appendix).

254

255	Vaccine Efficacy Modification by Baseline Parasite Positivity and Intercurrent New Infection
256	In the PP, 11.6% of participants (7.4% in Agogo and 16.0% in Siaya) were parasite positive at
257	baseline by microscopy and/or genotypic assay. The control-group incidence rate of the first
258	new infection was nearly three times higher in baseline positive (3.0 per person-year at risk
259	[PYR]) than baseline negative participants (1.2 per PYR), suggesting a correlation between
260	baseline positivity and infection risk; therefore, we also analyzed the cumulative number of new
261	genotypic infections (force of infection; FOI) detected after the first vaccination visit and by the
262	month 2 visit (M2-FOI). This covariate is an aggregate proxy of individual-level infection risk due
263	to many factors including seasonal transmission effects, local geography, susceptibility to
264	mosquito bites, and malaria prevention use. M2-FOI could potentially confound the VE-
265	modifying effect of baseline positivity, given that it was correlated with baseline positivity and the
266	calendar date of the first vaccination (Fig. S15–S16 in the Supplementary Appendix). We also
267	accounted for such potential confounding by adjusting for the indicator of the onset of
268	antimalarial drug treatment between the first vaccination visit and the month 2 visit (M2-mal-tx),
269	which correlated with baseline positivity (Fig. S17 in the Supplementary Appendix). Additional
270	VE-modification analyses were conducted adjusting for M2-FOI and M2-mal-tx, an adjustment
271	with minimal risk of post-randomization selection bias because vaccination had no discernible
272	effect on M2-FOI or M2-mal-tx (Fig. S18–S19 in the Supplementary Appendix). Adjusting for
273	M2-FOI, M2-mal-tx, sex, and age, VE of pooled R012-14, R012-20, and Fx012-14 vs. control to
274	prevent the first new genotypic infection in the PP was 37% (95% CI, 23 to 48%) among
275	baseline negative and 68% (95% CI, 50 to 80%) among baseline positive participants
276	(interaction P=0.0053) (Fig. 4; model M2-PP in Fig. S20 in the Supplementary Appendix). VE
277	modification by baseline positivity persisted when restricted to the early follow-up period
278	between 14 days and 4.5 months after the third dose (Fig. S21 in the Supplementary Appendix)
279	(interaction P=0.083), a period exhibiting relatively little waning of VE. The evidence for baseline

positivity as a modifier of VE was consistent across the two study sites, the individual RTS,S
regimens with dosing at M0, 1, 2, and the full PP vs. sensitivity 'third vaccination matching'
analysis (Fig. S22–S24 in the Supplementary Appendix).

283 As an indicator of intercurrent malaria infection between dose 1 and dose 3, M2-FOI has 284 a distinct interpretation compared to baseline positivity, motivating an exploratory analysis of 285 whether M2-FOI itself modifies VE. Adjusting for baseline positivity, M2-mal-tx, sex, and age, 286 VE of the same pooled RTS,S groups vs. control against the first new genotypic infection was 287 36% (95% CI, 22 to 48%) among PP participants with M2-FOI = 0 and 57% (95% CI. 39 to 288 69%) among PP with M2-FOI > 0 (interaction P=0.059) (Fig. 5; model M6-PP in Fig. S20 in the 289 Supplementary Appendix). VE modification evidence from a series of Cox models involving both 290 baseline positivity and M2-FOI, including model quality assessment, is summarized in Fig. S20 291 in the Supplementary Appendix for the genotypic infection endpoint. A sensitivity analysis, 292 reported in the Supplementary Appendix, concluded that the result of VE modification by 293 baseline positivity was robust to unmeasured confounding. 294 We do not report the impact of either baseline positivity or M2-FOI on VE against the first 295 new clinical malaria episode. Inference of this causal interaction effect is confounded by a 296 differential propensity of first clinical episodes arising due to persistent asymptomatic infections 297 acquired before the third vaccination, which are much more common in the baseline positive

and M2-FOI > 0 subgroups (**Table S5** in the Supplementary Appendix).

299

300 Discussion

The use of genotypically determined infection endpoints in this study has demonstrated unambiguously for the first time that RTS,S achieves some or all of the VE observed through blocking of infections before they reach the blood stage, with the RTS,S groups exhibiting a reduced number of new infections (**Fig. 2**) and a reduced risk of more highly polyclonal first

305 infections (Fig. 3). While the previous analysis of parasite genotypic features we performed on 306 specimens from the RTS,S phase 3 trial suggested this in the form of reduced COI,⁴ that study 307 only analyzed specimens from the first cases meeting the primary clinical case definition. 308 The genotypically determined infection endpoints yielded findings generally concordant 309 with the previous analysis of clinical disease endpoints with regard to the effects of RTS,S 310 vaccine dosage and regimen. While all RTS, S dosage regimens offer significant VE, none of the 311 regimens is superior for the follow-up period we examined. The genotypic endpoints we 312 examined suggest lower instantaneous VE in the Fx012-14 group several months after the third 313 dose (Fig. S7 in the Supplementary Appendix), suggesting that fractional dose regimens may 314 offer slightly less protection than full dose regimens administered on the same schedule. 315 Additionally, this study demonstrates several ways in which genotypically determined 316 infection endpoints complement clinical disease or microscopy-based infection endpoints. 317 Importantly, we observed that VE against the first new genotypically detected infection was 318 higher in participants who were baseline parasite-positive (asymptomatically infected with 319 malaria during their first vaccination). Participants who experienced more infections between 320 their first vaccination and month 2 visit (M2-FOI) did not exhibit abrogated VE and trended 321 towards greater protection. This suggests that active infection, and/or higher risk of infection, 322 potentiate RTS,S VE. Because baseline infection status and M2-FOI are correlated and these 323 features were not randomized in the study design, distinguishing their relative impacts is difficult 324 from the current data. Further, we cannot presently distinguish whether variation in infection risk 325 among participants is due to environmental, immunological, or other factors. However, active 326 infections at the time of first vaccination could affect VE by the prior priming of CS-specific T-327 helper cells provided by natural infection, resulting in enhanced production of protective 328 antibodies and/or a more effective cellular immune response during the liver stage. Similarly, 329 the non-significant trend towards greater VE observed in participants with M2-FOI > 0 could be

driven by repeated natural exposure to CS antigen from infectious mosquito bites as a form ofheterologous prime-boost.

The observation of increased RTS,S protection in baseline-infected/M2-FOI > 0 332 333 participants is unexpected. A large number of studies have documented immunosuppressive effects of acute or asymptomatic malaria infection in various human or rodent model contexts¹⁵⁻ 334 335 ²⁰, and these observations have led to the hypothesis that erythrocytic-stage malaria infection at 336 the time of vaccination may compromise the development of an efficacious immune response, measured at the level of either clinical disease⁵ or molecularly detected infection.⁶ However, a 337 338 recent analysis of RTS,S efficacy in the phase 3 clinical trial found that protection against clinical malaria was unaffected by infection status during vaccination.²¹ Our work is the first to 339 340 demonstrate a positive association between erythrocytic infection present at the first vaccination 341 and VE against infection, and indicates that discordant findings in studies focusing on malarianaive adults⁶ or mouse models²⁰ may reflect fundamentally different mechanisms of pre-342 343 erythrocytic immunity development. Future studies will be required to understand this apparent 344 discordance.

345 There are several important consequences of the observation of greater RTS, S VE in association with baseline parasite positivity and infection risk. First, this finding indicates that 346 347 future studies of the efficacy of RTS,S and other candidate malaria vaccines may need to take 348 into account local transmission level and/or heterogeneity in infection risk among participants, 349 as differential VE against infection and/or clinical disease as a function of baseline infection 350 status or infection risk could influence vaccine deployment strategy. Second, this finding 351 motivates the inclusion of genotypic endpoints in future intervention studies to further assess the 352 effects of baseline infection status and molecular FOI, as well as immune assays to understand the mechanism of the protective effect.²² Future studies should directly address the impact of 353 354 baseline positivity and infection risk on VE against clinical disease, which we do not report here 355 because the interaction effect of treatment and the potential VE modifier is confounded by

356 differential opportunity among subgroups for the first clinical cases to be associated with asymptomatic infections acquired before the third vaccination, which may increase the risk of 357 subsequent clinical disease.²³ Additionally, this finding could lead designers of future vaccine 358 359 and monoclonal antibody (mAb) field trials to re-evaluate the practice of diagnosing and clearing pre-existing malaria infections from subjects during enrollment, a common approach²⁴⁻²⁶ that 360 361 may limit the approved use of an intervention to uninfected recipients if it is later licensed. 362 Genotyping the monthly cross-sectional samples collected from all subjects in this study 363 has provided an unprecedented view of asymptomatic and polyclonal infection dynamics in a 364 natural setting. The evaluation of future malaria interventions with comparable data will enable 365 direct measurement of their potential not only to mitigate clinical cases, but also to achieve local 366 disease elimination.

367

368 **Disclosure**

369 The findings and conclusions in this article are those of the authors and do not necessarily

370 represent the views of the U.S. Centers for Disease Control and Prevention or the U.S.

371 Department of Health and Human Services.

372 Trademark

AS01 is a trademark owned by or licensed to the GSK group of companies.

374 Conflicts of Interest

375 LDM received grants from the Bill and Melinda Gates Foundation and KfW/BMBF (German

376 Federal Ministry of Education and Research) through her institution. CKL received a grant

377 from KfW/BMBF (German Federal Ministry of Education and Research) and a grant from Bill

and Melinda Gates Foundation. DFW acted as a PI on this MAL-095 study funded by a PATH

grant paid to Harvard University, which also supported DEN, AME, BLM, SFS, and AK. DFW

is also Chair of the MPAG (Malaria Policy Advisory Group) that advises the WHO on all

malaria policy. PBG discloses a PATH subaward from Harvard for statistical analysis
contributing to salary support for PBG, MJ, and LL. AME, LL, AK,BS, NSH, DB, SAdjei, TA,
SA, DA, DKB, PBYB, SE, NF, JG, SKK, KO, AMS, NW, CFO declare no conflict of interest.
ML, FR, OO-A are employees of GSK.ML, FR, and OO-A own shares in GSK. The authors
declare no other financial and non-financial relationships and activities.

386

387 Acknowledgements

388 Funding for this trial and publication was provided by GlaxoSmithKline Biologicals SA (study 389 sponsor) and by PATH, an international public health organization, through grants awarded to 390 PATH's Center for Vaccine Innovation and Access by the Bill & Melinda Gates Foundation and the German Federal Ministry of Education and Research (the latter administered through the 391 392 KfW Development Bank). The authors and trial partners thank the study participants and their 393 parents/caregivers, and the RTS,S MAL-094 Study Group for their participation and support of 394 malaria clinical research. This work was also partially supported by the National Institute of 395 Allergy and Infectious Diseases, NIH, under award R37AI054165 (to PBG). We wish to thank 396 the Broad Institute Genomics Platform for sample processing and data generation, in particular, 397 Jody Camarata, Natasha Smith, and Rachael Barry. We also thank Susanna Hamilton, Chad 398 Max, and Kalyn Hubbard for product management and Nithya Swaminathan for project 399 management at the Broad Institute. We thank the following PATH colleagues: Scott Gregory for project management and Karen Ivinson for IRB submissions. We thank Anne Bollaerts (GSK) 400 401 for data analysis and Hildegard Lemaire for sample management at GSK. Business & Decision 402 Life Sciences platform provided editorial assistance and manuscript coordination, on behalf of GSK. 403

404 **Contributions**:

- 405 MJ, ML, LDM, SAdjei, TA, DA, DKB, PBYB, SKK, KO, AMS, NW, CFO, CKL, BLM, DFW, PBG,
- 406 and DEN contributed to the study design and methods. AME, AK, SAdjei, TA, SAnderson, DKB,
- 407 PBYB, SE, NF, JG, SKK, KO, FR, AMS, NW, OO-A, DFW, and DEN were responsible for data
- 408 acquisition. MJ, AME, LL, SFS, ML, BS, NSH, DB, LDM, DA, DKB, PBYB, SKK, KO, AMS, NW,
- 409 CFO, CKL, BLM, DFW, PBG, and DEN performed data analysis, and/or data interpretation. All
- 410 authors read and edited the manuscript. All authors approved the final version and the decision
- 411 to submit the manuscript. All authors had full access to all the data and had final responsibility
- 412 for the decision to submit for publication.
- 413

414 **References**

415

- 416 1. World malaria report 2022 [Internet]. [cited 2023 May 17];Available from:
 417 https://www.who.int/publications-detail-redirect/9789240064898
- 418 2. Galatas B, Bassat Q, Mayor A. Malaria Parasites in the Asymptomatic: Looking for the Hay
 419 in the Haystack. Trends Parasitol 2016;32(4):296–308.
- 3. Samuels AM, Ansong D, Kariuki SK, et al. Efficacy of RTS,S/AS01E malaria vaccine
 administered according to different full, fractional, and delayed third or early fourth dose
 regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b,
 randomised controlled trial. Lancet Infect Dis 2022;22(9):1329–42.
- 424 4. Neafsey DE, Juraska M, Bedford T, et al. Genetic Diversity and Protective Efficacy of the 425 RTS,S/AS01 Malaria Vaccine. N Engl J Med 2015;373(21):2025–37.
- 426 5. Oneko M, Steinhardt LC, Yego R, et al. Safety, immunogenicity and efficacy of PfSPZ
 427 Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo428 controlled phase 2 trial. Nat Med 2021;27(9):1636–45.
- Murphy SC, Deye GA, Sim BKL, et al. PfSPZ-CVac efficacy against malaria increases
 from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A
 randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog
 2021;17(5):e1009594.
- 433 7. Gilbert PB, Wei LJ, Kosorok MR, Clemens JD. Simultaneous inferences on the contrast of
 434 two hazard functions with censored observations. Biometrics 2002;58(4):773–80.
- 435 8. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics Based on
 436 Weighted Residuals. Biometrika 1994;81(3):515–26.
- Porter KE, Gruber S, van der Laan MJ, Sekhon JS. The relative performance of targeted
 maximum likelihood estimators. Int J Biostat 2011;7(1):31.
- 439 10. Juraska M, Gilbert PB. Mark-specific hazard ratio model with missing multivariate marks.
 440 Lifetime Data Anal 2016;22(4):606–25.
- Heng F, Sun Y, Gilbert PB. Estimation and Hypothesis Testing of Strain-Specific Vaccine
 Efficacy with Missing Strain Types, with Applications to a COVID-19 Vaccine Trial
 [Internet]. 2022 [cited 2023 Mar 4]:Available from: http://arxiv.org/abs/2201.08946
- [Internet]. 2022 [cited 2023 Mar 4]; Available from: http://arxiv.org/abs/2201.08946
 Juraska M, Gilbert PB. Mark-specific hazard ratio model with multivariate continuous

- 445 marks: an application to vaccine efficacy. Biometrics 2013;69(2):328–37.
- 446 13. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. Scand J Stat
 447 1979;6(2):65–70.
- 448
 448
 449
 449
 449
 449
 440
 440
 441
 441
 441
 442
 442
 443
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
- 450 15. Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A. Immunosuppression in children
 451 with malaria. Lancet Lond Engl 1972;1(7743):169–72.
- 452 16. McBride JS, Micklem HS. Immunosuppression in murine malaria. II. The primary response
 453 to bovine serum albumin. Immunology 1977;33(2):253–9.
- 454 17. Whittle HC, Brown J, Marsh K, et al. T-cell control of Epstein-Barr virus-infected B cells is
 455 lost during P. falciparum malaria. Nature 1984;312(5993):449–50.
- Ho M, Webster HK, Looareesuwan S, et al. Antigen-specific immunosuppression in human
 malaria due to Plasmodium falciparum. J Infect Dis 1986;153(4):763–71.
- 458 19. Bejon P, Mwacharo J, Kai O, et al. The induction and persistence of T cell IFN-gamma
 459 responses after vaccination or natural exposure is suppressed by Plasmodium falciparum.
 460 J Immunol 2007;179(6):4193–201.
- 461 20. Keitany GJ, Kim KS, Krishnamurty AT, et al. Blood Stage Malaria Disrupts Humoral
 462 Immunity to the Pre-erythrocytic Stage Circumsporozoite Protein. Cell Rep
 463 2016;17(12):3193–205.
- Bell GJ, Gyaase S, Goel V, et al. Malaria Transmission Intensity and Parasitemia during
 the Three-Dose RTS,S/AS01 Vaccination Series do not Reduce Magnitude of Antibody
 Response nor Efficacy Against the First Case of Malaria [Internet]. In Review; 2023 [cited
 2023 Jun 8]. Available from: https://www.researchsquare.com/article/rs-2960373/v1
- 468 22. Mueller I, Schoepflin S, Smith TA, et al. Force of infection is key to understanding the
 469 epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl
 470 Acad Sci U S A 2012;109(25):10030–5.
- 471 23. Sumner KM, Mangeni JN, Obala AA, et al. Impact of asymptomatic Plasmodium falciparum
 472 infection on the risk of subsequent symptomatic malaria in a longitudinal cohort in Kenya.
 473 eLife 2021;10:e68812.
- 474 24. Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of PfSPZ Vaccine against
 475 Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in
 476 Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 2017;17(5):498–509.
- 477 25. Kayentao K, Ongoiba A, Preston AC, et al. Safety and Efficacy of a Monoclonal Antibody
 478 against Malaria in Mali. N Engl J Med 2022;387(20):1833–42.
- 479 26. Sissoko MS, Healy SA, Katile A, et al. Three dose regimen of PfSPZ Vaccine protects
 480 adult Malians against Plasmodium falciparum through an intense transmission season: a
 481 randomised, controlled phase I trial. Lancet Infect Dis 2022;22(3):377–89.
- 482

483 **Figure Captions**

- Figure 1. Cumulative incidence and vaccine efficacy against the first new genotypic infection for
- the PP cohort. First new genotypic infection (A) between 14 days after month 2 through month
- 486 14 for R012-14 plus R012-20 and Fx012-14 vs. the control regimen and (B) between 14 days
- 487 after month 7 through month 19 for Fx017-20 vs. the control regimen. (C) Forest plot of vaccine

488 efficacies against the first new infection vs. the control regimen. PYR: person-year at risk; VE: 489 vaccine efficacy; CI: confidence interval; PP: Per Protocol cohort; No: number. 490 491 Figure 2. Reverse cumulative distribution function and vaccine effect on the number of new 492 molecular infections in the Per-Protocol (PP) cohort (A) between 14 days after month 2 through 493 month 14 for R012-14 plus R012-20 and Fx012-14 vs. the control regimen and (B) between 14 494 days after month 7 through month 19 for Fx017-20 vs. the control regimen. (C) Forest plot of 495 vaccine effects on the mean number of new infections vs. the control regimen. CI: confidence 496 interval; PP: Per Protocol cohort; No: number; Diff: Difference. 497

498 Figure 3. Comparisons of Complexity of infection (COI) of first new genotypic infections between

the pooled R012-14, R012-20, and Fx012-14 RTS,S regimens vs. the control regimen (for new

500 infections between 14 days after month 2 through month 13) and Fx017-20 vs. the control

regimen (for new infections between 14 days after month 7 through month 19) for the Per-

502 Protocol (PP) cohort: (A), (C) frequencies and (B), (D) risk reduction (1 – hazard ratio) against

503 the first new genotypic infection with a given level of COI.

504

505 Figure 4. (A) Cumulative incidence and (B) vaccine efficacy against the first new genotypic

infection between 14 days after month 2 through month 14 for the pooled R012-14, R012-20,

and Fx012-14 RTS,S regimens vs. the control regimen for the Per-Protocol (PP) cohort by

508 baseline malaria infection status while adjusting for month 2 force of infection (M2-FOI). PYR:

509 person-year at risk; VE: vaccine efficacy; CI: confidence interval; No: number.

510

511 Figure 5. (A) Cumulative incidence and (B) vaccine efficacy against the first new genotypic

512 infection between 14 days after month 2 through month 14 for the pooled R012-14, R012-20,

and Fx012-14 RTS,S regimens vs. the control regimen for the per-protocol (PP) cohort by

- 514 month 2 FOI (M2-FOI) = 0 vs. > 0. PYR: person-year at risk; VE: vaccine efficacy; CI:
- 515 confidence interval; No: number; M2-FOI: month 2 force of infection.

516

517



C	
L	

Treatment Comparison	No. of First New Infections	VE (%) (95% CI)	2-Sided
	(Incidence per PYR)		P-value
R012-14 plus R012-20 vs. Control	282 (0.87) vs. 176 (1.28)	42.8 (30.7, 52.8)	► < 0.001
Fx012–14 vs. Control	160 (0.94) vs. 176 (1.28)	36.7 (21.2, 49.2)	► < 0.001
Fx017–20 vs. Control	145 (0.95) vs. 174 (1.51)	41.4 (26.7, 53.1)	► < 0.001
			0 20 40 60
			VE (%) (95% CI)

Figure 1. Cumulative incidence and vaccine efficacy against the first new genotypic infection for the PP cohort.



Figure 2. Reverse cumulative distribution function and vaccine effect on the number of new molecular infections in the PP cohort.



Figure 3. Comparisons of Complexity of infection (COI) of first new genotypic infections between the pooled R012-14, R012-20, and Fx012-14 RTS,S regimens vs. the control regimen (for new infections between 14 days after month 2 through month 13) and Fx017-20 vs. the control regimen (for new infections between 14 days after month 7 through month 19) for the Per-Protocol (PP) cohort: (A), (C) frequencies and (B), (D) risk reduction (1 – hazard ratio) against the first new genotypic infection with a given level of COI.



Figure 4. (A) Cumulative incidence and (B) vaccine efficacy against the first new genotypic infection between 14 days after month 2 through month 14 for the pooled R012-14, R012-20, and Fx012-14 RTS,S regimens vs. the control regimen for the Per-Protocol (PP) cohort by baseline malaria infection status while adjusting for month 2 force of infection (M2-FOI). PYR: person-year at risk; VE: vaccine efficacy; CI: confidence interval; No: number.

Baseline	No. of First New Infections			Interaction
Positivity	(Incidence per PYR)	VE (%) (95% CI)		P-value
Negative	374 (0.85) vs. 148 (1.16)	36.5 (23.0, 47.6)		0.0053
Positive	68 (1.25) vs. 28 (3.02)	68.0 (50.1, 79.5)	FB1	
			0 20 40 60 80 VE (%) (95% CI)	



Figure 5. (A) Cumulative incidence and (B) vaccine efficacy against the first new genotypic infection between 14 days after month 2 through month 14 for the pooled R012-14, R012-20, and Fx012-14 RTS,S regimens vs. the control regimen for the per-protocol (PP) cohort by month 2 FOI (M2-FOI) = 0 vs. > 0. PYR: person-year at risk; VE: vaccine efficacy; CI: confidence interval; No: number; M2-FOI: month 2 force of infection.

M2-FOI	No. of First New Infections (Incidence per PYR)	VE (%) (95% CI)		Interaction P-value
0	328 (0.79) vs. 128 (1.07)	36.1 (21.4, 48.0)		0.059
1-3	114 (1.42) vs. 48 (2.79)	56.5 (38.7, 69.1)	⊢	
			0 20 40 60 80 VE (%) (95% CI)	